Tezspire Insurance Denied? How to Appeal Your Tezepelumab Asthma Denial

Tezspire (tezepelumab) is a breakthrough asthma biologic that stands apart from its competitors: it's the only asthma biologic that works regardless of eosinophil count, blood IgE level, or allergic status. FDA-approved for severe, uncontrolled asthma in adults and adolescents 12 and older, Tezspire targets TSLP (thymic stromal lymphopoietin) — an upstream alarmin that initiates the entire allergic cascade. Despite this unique clinical profile, insurance denials for Tezspire are common. Here's how to fight back.

What Tezspire Treats and Why Patients Need It

Tezspire works by blocking TSLP, a cytokine released by epithelial cells in response to triggers like allergens, viruses, and pollutants. TSLP sits at the very top of the allergic inflammatory cascade — before eosinophil, IgE, or mast cell activation. By blocking TSLP, tezepelumab reduces multiple downstream pathways simultaneously.

This upstream mechanism gives Tezspire a key advantage: it works across asthma phenotypes. Other biologics require elevated eosinophils (Nucala, Fasenra), high IgE with allergen sensitization (Xolair), or elevated eosinophils or OCS dependence (Dupixent). Tezspire is the only asthma biologic with FDA approval that does not require any specific biomarker threshold.

In the NAVIGATOR Phase 3 trial, Tezspire reduced annualized exacerbation rates by 70% in patients with severe, uncontrolled asthma across all eosinophil subgroups — including those with very low eosinophil counts who would not qualify for other biologics.

Common Denial Reasons for Tezspire

Step therapy requirements: Insurers commonly require patients to try and fail other asthma biologics — often Xolair, Nucala, Fasenra, or Dupixent — before approving Tezspire. This is clinically problematic when Tezspire is the biologic specifically indicated for patients who don't meet the biomarker criteria for other agents.

Eosinophil threshold applied inappropriately: Some plans apply PCSK9 inhibitor-style biomarker criteria even to Tezspire, incorrectly requiring eosinophils ≥150 or ≥300 — despite the FDA approval placing no such restriction.

"Newer agent" / insufficient long-term data: Some plans are slow to add Tezspire to formulary or cite limited real-world data as a reason to defer coverage.

Preferred biologic not tried first: Plans may require trials of their preferred formulary biologics, which often have preferred rebate contracts with the insurer, before approving a non-preferred agent like Tezspire.

Severity documentation insufficient: Uncontrolled asthma definition varies — plans typically require documented exacerbations (≥2 annually requiring systemic corticosteroids or hospitalization).

Step-by-Step: How to Appeal a Tezspire Denial

Step 1: Identify the denial reason. If denied for failing to meet an eosinophil threshold, this is particularly important — the FDA label for Tezspire has no eosinophil cutoff.

Step 2: Have your pulmonologist or allergist write a Letter of Medical Necessity. The LMN should explain your asthma severity, exacerbation history, current medications, prior biologic trials (if any), and why Tezspire is specifically appropriate — particularly if you don't meet biomarker criteria for other biologics.

Step 3: Challenge inappropriate biomarker requirements. Include the FDA prescribing information for Tezspire explicitly noting no eosinophil count or IgE threshold is required for approval. Quote the label directly.

Step 4: Document your exacerbation history. Show ≥2 exacerbations per year requiring systemic corticosteroids, ER visits, or hospitalization.

Step 5: Document failure of conventional maximized therapy. High-dose ICS/LABA, LAMA, and other controller medications should be documented with inadequate response.

Step 6: File the internal appeal with complete documentation and request peer-to-peer review.

Step 7: File an external appeal if needed. External Independent Review: Complete Guide" class="auto-link">External reviewers who see the FDA label language directly will have difficulty sustaining a denial based on a biomarker threshold the FDA didn't require.

What to Include in Your Tezspire Appeal Letter

• Policy number, member ID, and claim reference
• Tezspire (tezepelumab) prescribed dose and indication
• Asthma exacerbation history (dates, severity, treatment required)
• Current asthma medications and doses (ICS, LABA, LAMA, etc.)
• Eosinophil count if available (and statement that biomarker cutoff does not apply per FDA label)
• Prior asthma biologic trials if any
• Letter of Medical Necessity from pulmonologist or allergist
• Tezspire FDA prescribing information excerpt: "no biomarker threshold required"
• NAVIGATOR trial citation (70% exacerbation reduction, all eosinophil subgroups)
• GINA severe asthma add-on therapy guidelines
• Challenge to any biomarker-based denial criteria that contradict the FDA label

Success Tips for Tezspire Appeals

Use the FDA label as your weapon. The FDA prescribing information for Tezspire explicitly contains no eosinophil or IgE threshold. If a plan's coverage criteria impose thresholds the FDA didn't require, cite the label directly and argue that the plan's criteria are more restrictive than the regulatory evidence supports.

Highlight the no-biomarker advantage. Many patients who need Tezspire are precisely those who don't qualify for other biologics due to low eosinophils or negative allergy tests. This is the clinical niche Tezspire was designed for. Make this argument explicitly in your appeal.

Quantify the uncontrolled disease. Use the validated ACQ-6 (Asthma Control Questionnaire) or AQLQ scores to document your level of asthma control. Scores demonstrating poorly controlled asthma despite maximum therapy make a compelling case.

Request peer-to-peer with your pulmonologist. Physicians who can explain the pharmacological rationale for TSLP inhibition in non-T2 asthma or mixed phenotype patients often change the outcome in peer-to-peer reviews.

Fight Back With ClaimBack

Tezspire was approved to help patients with severe asthma who have nowhere else to turn — particularly those who don't meet biomarker criteria for other biologics. A denial based on inapplicable criteria can and should be appealed. ClaimBack helps you make that case effectively.

Start your Tezspire appeal at ClaimBack

Related Reading

• How to Write an Insurance Appeal Letter
• What Is Medical Necessity?
• Internal vs. External Insurance Appeals